LQT Therapeutics nabs $19m in Amplitude-led Series A round

Laval, Quebec-based LQT Therapeutics, a pharmaceutical company focused on developing precision therapies for genetic heart diseases, has secured $19 in a Series A financing.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this